Given that hepatic PPARγ acts as a transcription factor that promotes de novo lipogenesis, and increases hepatic triglyceride accumulation, our objective is to examine whether exercise intervention modulates the activity of PPARγ during the progression of NAFLD. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatotic liver disease.